The strong Q3 beat and termination of the ATM offering remove a near-term overhang. Monitor the Q4 2026 signing of the new $3M credit line and any guidance updates in the next 10-Q.
Price Chart
How similar events traded
Executive Summary
ImmuCell filed an 8-K/A to fix a broken hyperlink in its original 8-K earnings release. The underlying Q3 2026 results show product sales up 46% to $8.0M, net income of $953K vs a loss of $140K a year ago, and the termination of the At-The-Market offering. The amendment itself is purely administrative with no new financial information.
Key Facts
- Q3 2026 product sales rose 46.0% to $8.0M from $5.5M in Q3 2025
- Net income was $953K ($0.10/diluted share) vs a net loss of $140K ($0.02 loss per basic share) in Q3 2025
- Gross margin improved to 44.2% from 42.9%
- Adjusted EBITDA was $1.9M vs $0.8M in Q3 2025
- Cash and cash equivalents increased to $7.9M from $3.8M at Dec 31, 2025
- Company terminated its At-The-Market offering and negotiated a new $3M line of credit expected to close in Q4 2026
- The 8-K/A only fixes a broken hyperlink in the original 8-K; no financial changes
Financial Impact
Revenue up 46% YoY to $8.0M; net income swing of +$1.1M to $953K; cash balance doubled to $7.9M
Risk Factors
- Revenue growth was aided by absence of prior-year distributor destocking headwinds, which may not repeat
- Sales, marketing and administrative expenses grew 47% YoY, outpacing gross profit growth in absolute dollars
- Small-cap stock with limited liquidity and $103M market cap
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K/A Filing (Primary) | 0001437749-26-037731 |
| Document: iccc20261118_8ka.htm | 0001437749-26-037731 |
| Document: 0001437749-26-037731-index-headers.html | 0001437749-26-037731 |
| Document: 0001437749-26-037731-index.html | 0001437749-26-037731 |
| Document: 0001437749-26-037731.txt | 0001437749-26-037731 |
Track record
8 reports on ICCC
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +27.22% at T+60 after the May 8, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 19, 20262d ago 8-K/A Bullish 5/10 Viewing Entry $11.27 Now $10.92 −3.13% settles Nov 30
- Nov 12, 20269d ago Press Release Bullish 5/10 Entry $10.75 to $10.92 Now $10.92 +1.58% ▲ +1.58% +10.14% vs SPY
- Oct 13, 20265w ago 8-K Bullish 6/10 Entry $10.79 to $10.45 Now $10.92 +1.20% ▼ −3.15% −2.00% vs SPY
- May 8, 202628w ago 8-K Bullish 4/10 Entry $8.45 to $9.91 Now $10.92 +29.23% ▲ +17.28% +17.36% vs SPY
- Apr 8, 202632w ago 8-K Bullish 7/10 No price data
- Apr 8, 202632w ago Press Release Mixed 6/10 Entry $7.19 to $7.54 Now $10.92 +51.88% ▲ +4.87% +1.68% vs SPY
- Mar 4, 202637w ago 8-K Mixed 6/10 Entry $6.35 to $6.63 Now $10.92 +71.97% ▲ +4.41% +6.65% vs SPY
- Mar 4, 202637w ago Press Release Mixed 6/10 Entry $6.35 to $6.63 Now $10.92 +71.97% ▲ +4.41% +6.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers